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Abstract 
Opioid substitution treatment (OST) reduces the harm of injecting and opioid dependence. The SCID 
feasibility trial explored the processes of conducting a randomised control trial (RCT) with people 
who inject drugs (PWID) in a low threshold agency. Feasibility of the intervention investigated 
whether offering PWID immediate access to OST via specialist primary care increased numbers in 
OST at 3 months, compared to offering advice and case management.  
 
Methods 
Un-blinded RCT was conducted at Bristol Drugs Project needle exchange. A total of 311 individuals 
were eligible and 100 consented to participate. Trial process outcomes involved exploring OST status 
at 3 months; secondary outcomes were substance use and health related quality of life measures. 
 
Results 
Follow-up was 86%.  At 3 months, 51% intervention and 47% of control participants were in OST (OR 
of success of intervention 1.17 (0.54-2.57). Opioid use reduced by 79% and 73% respectively (OR of 
intervention success 1.38 (0.5-3.7).  Physical and mental health improved but there was little 
differences between groups.  
 
Conclusions 
The feasibility of conducting the trial was a success, but there was insufficient evidence of an effect 
compared to intensive case management.  Further development and evaluation of case 
management approaches in low-threshold agencies is warranted. 
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Introduction 
Opioid substitution treatment (OST) reduces the harm of injecting and opioid dependence: reducing 
drug related mortality, the frequency of injecting, Hepatitis C Virus, HIV, and drug related crime (1-
6). Prolonged treatment has a positive effect on overall survival and prevalence of blood borne 
viruses (7, 8).  Promoting OST and reducing the time out of treatment, therefore, is a key goal in the 
prevention of drug related harm.    
 
There is evidence that motivational interviewing and intensive case management can increase 
treatment onset (9, 10). Recent meta-analyses suggest that exposure to motivational interviewing or 
case management intervention increases the likelihood of entering treatment by 1.69 and 3 times 
respectively (9). However, generalising the studies to a UK population is problematic as all were US 
based, in contexts where treatment was not free at point of delivery. Furthermore, brief 
interventions and case management to encourage OST uptake are already in place in low threshold 
agencies in contact with people who inject drugs (PWID) in many sites in the UK.  In designing the 
current trial, we involved PWID and drug workers and their favoured option was for the provision of 
immediate low threshold access to OST.  This has already been developed in Amsterdam with mobile 
access to OST (11, 12).  In many sites in the UK there is ready access to primary care , which delivers 
the majority of OST (13).  Therefore, we designed an intervention “Script in a Day” (SCID) that would 
offer immediate access to OST through referral to a local specialist primary care centre (14).  In this 
feasibility study we test whether PWID can be recruited and followed-up and whether we can 
evaluate if receiving SCID increases the number of patients in OST at 3 months after exposure 
compared to treatment as usual within a randomised control trial. 
 
  
4 
Methods  
Study design  
This feasibility trial explored the processes of conducting a small scale RCT. An un-blinded parallel-
group trial tested the feasibility of the intervention which offered same day access to opioid 
substitution therapy (OST), described as “Script in a Day”, compared with standard care with 3 
month follow-up.  
 
Recruitment 
Recruitment took place on two days a week (when slots with the GP were available) at the Bristol 
Drugs Project (BDP) low threshold agency (also known as “direct access” in the UK) between October 
2011 and September 2012 (Figure 1).  Drug workers or volunteers approached potentially eligible 
adults who were accessing the needle syringe programme (NSP).  Eligibility requirements were: 
living in Bristol; not prescribed OST in the last two weeks; and injecting opioids. Participants were 
given detailed information about the study, time to reflect whether they wished to participate and 
questions answered before being consented into the study. Participants completed baseline 
questionnaires with the assistance of the research staff before being randomised to the “Script in a 
Day” intervention or standard care.  Data collected at baseline and 3 month follow-up included: the 
Treatment Outcomes Profile Measure (TOP) which is widely used in drug services and measures 
substance use; injecting risk behaviour and crime (15, 16); and two health related quality of life 
measures EQ-5D-5L (17) and  the SF-12-v1 (18). Randomisation was a web-based allocation provided 
by Bristol Randomised Trial Collaboration (BRTC) using random sized blocks and stratifying by sex. 
Participants were invited to return the following day to receive £15. Participants also received £15 at 
the three month follow-up.  Ethics approval was given by National Research Ethics Service, South 
West, [11/H0102/1]. 
 
Usual care was defined as offering participants advice and information about obtaining a script and if 
wished, help with making a telephone call to their general practitioner (GP) to initiate this 
process(9).  
 
Script in a Day Intervention 
The Script in a Day Intervention involved one GP practice agreeing to keep open appointment slots 
twice a week for intervention participants. Participant details were faxed to the intervention GP who 
requested a fax from the participant’s GP prior to the appointment to avoid double scripting. 
Participants were offered the support of a peer support volunteer on the 15 minute walk to the GP 
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surgery.  This is part of the volunteer role at BDP and we included this as part of the feasibility study. 
On arrival, participants provided a urine sample to check for the presence of opioids using Drug-
Screen-Multi 5MB, and if screen positive and no other contra-indications, participants were initiated 
on 30-40ml of methadone, which was taken on the day. A further script for 6 days was issued and 
participants were asked to return on Day 7 and 21 for further scripts and if required adjustments 
between 10-20ml. From Day 21 participants were transferred to their GP practice and shared care 
worker when spaces became available.  
 
Outcome measures 
The feasibility outcomes were numbers recruited, randomised and outcome data collected at 3-
months.Follow-up was conducted through self-report and data linkage via medical, BDP and other 
drug treatment agencies’ records. At baseline and 3 months we assessed drug use (TOP), and quality 
of life (EQ-5D-5L and SF-12-v1) using questionnaires administered face-to-face. From these, we 
derived Quality Adjusted Life Years (QALYs). QALYs are a measure of health status whereby survival 
is weighted by quality of life.   
 
Data were analysed using 95% confidence intervals (CI) for all outcome measures in preference to p 
values as this feasibility study was not powered for hypothesis testing.  Confidence intervals for 
percentages were calculated using the exact binomial method.  Effect sizes for the difference from 
baseline to 3 months were calculated using the standard deviation for a paired t-test and assumes 
that the distribution of the differences was normally distributed.  Effect sizes for the effect of the 
intervention were calculated using a regression model controlling for baseline value and used the 
standard deviation associated with the test statistic for the coefficient. OST at 3 months post 
randomisation was investigated using a Kappa statistic to compare self-report with medical records 
checks.  Health related quality of life (SF-12-v1) produced 8 domains with two aggregate measures: a 
physical and a mental component. Those reported here are standardised as scores out of 100 for 
direct comparison across domains and for comparison with the EQ-5D visual analogue score (VAS). 
Preference weights for the UK population were obtained at baseline and 3 months for the EQ-5D-5L 
using the cross-walk algorithm(19), and for the SF-6D (six domains derived from the SF-12) using 
Brazier’s algoritm(20).  Quality of life preference weights are country-specific and range from 
negative values for health states worse than death, zero for death and up to one for the “best 
imaginable health”.  Three month QALYs were derived calculating the area under the curve by 
treatment arm and adjusting for baseline scores (21) .  
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A nested qualitative study explored trial processes with a purposive sample of 20 participants that 
included both intervention (8) and control groups (12).  Semi-structured interviews guided by a topic 
guide were conducted and data thematically analysed (for more detail see our companion paper 
(22).  
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Results 
A total of 311/1,371 individuals assessed were eligible and 100/311 consented (Figure 2 Participant 
Flow Diagram).  Reasons for declining included being too busy or not interested in receiving a script. 
The vast majority (881/1060 (83%)) of participants screened were excluded because they were 
already on a script.  The remaining were either not on a script (n=35), not injecting opioids (n=111), 
not living in Bristol (n=13) or not recorded (n=20). The participants comprised 84 men and 16 
women; 93.4% were white, 69% were registered with a GP, 26% had no fixed abode, and 90% had 
previously received OST (Table I). These characteristics are similar to people who inject drugs (PWID) 
attending local services (e.g. PWID attending needle syringe programme.  Feasibility outcomes are 
shown in Table II. Forty nine participants were allocated to the intervention, of which 43 received a 
script, two did not arrive at the GP practice, three were already scripted and in one, no opioids were 
detected in the urine and so could not receive a prescription.   
Most intervention arm participants chose to be accompanied to their GP appointment by a peer 
volunteer and appreciated the positive reinforcement and role model for recovery that this afforded 
(see box 1). 
 
Box 1: quotes from participants about peer volunteers here 
 
Overall, follow-up was 86% (84% intervention and 86% control) through interview, 90% through 
medical records (98% intervention and 80% control), and 95% (97% intervention and 92% control) 
from interview or medical records.  
 
Table I and II here 
 
Outcome measures 
There was good agreement between the two methods of follow up for 79 participants with both 
self-report and medical records OST at 3 months (Kappa of 0.872).  Self-report rates of OST at 3 
months were slightly higher at 59.5% (47/79) than medical report rates 53.2% (42/79) with 
discrepancies occurring in a few individuals on OST sporadically over the follow up time.  Combining 
the results suggested that there were 49 patients on OST at 3 months.  The intention to treat 
analysis assumed that those lost to follow-up were not in OST at 3 months.  Overall, 51% and 47% of 
the intervention and control participants were in OST (OR of success of intervention 1.17 95% CI 0.54 
to 2.57, Table III).  
 
Table III here 
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There were substantial reductions in self-reported opioid use in both the intervention and control 
population (33.3% and 22.7% not having used in the last 28 days) but insufficient evidence of any 
differences in effect between intervention and control (OR of intervention success 1.38 95% CI 0.5 to 
3.7).  Table IV shows the change in self-reported substance use between baseline and 3 months 
(expressed as standardised effect sizes corresponding to mean difference divided by the standard 
deviation of this difference).  Effect sizes showed that being in the study had a large effect on both 
the number of days of opioid use and number of days injecting drug use, a moderate to strong effect 
on crack use, but little impact on alcohol or other drug use. Differences between the intervention 
and control group were less marked but there was a small difference in reduction of opioid use of 2 
days, in contrast to overall average reduction in opioid use for all trial (control and intervention) 
participants of 14 days.   
 
Table IV here 
 
There were improvements in HRQL over the three months. These were medium effect sizes for both 
the EQ-5D and all the components of the SF-12.  The intervention was associated with a small non-
significant decrease in the overall HRQL score with the EQ-5D, but a positive medium sized effect for 
the mental health quality of life aggregate score for the SF-12, which was present in all the mental 
health domains. For participants completing both the EQ-5D and the SF-12, there was no evidence of 
incremental QALY gains between arms, -0.006 [95% CI -0.020 to 0.008] using the EQ-5D and 0.003 
[95% CI -0.005 to 0.010] using the SF-6D (Table V). In this group the distribution of SF-6D scores 
displayed less variability and baseline imbalance than for the EQ-5D scores (Figure 3). 
 
Table V & Figure 4 here 
 
Qualitative interviews showed that completing the baseline questionnaires at recruitment appeared 
to enhance motivation for treatment for all participants. For some control participants, this 
motivation seemed to increase a sense of self-efficacy and cognitive dissonance generated between 
their current health state and own aspirations was resolved by seeking treatment from their GP (22).  
 
Box 2 quotes from participants illustrating how taking part in the trial increased self-efficacy and 
motivation here. 
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DISCUSSION 
Main findings 
This feasibility trial of script in a day (SCID), whereby peer support volunteers facilitate ready access 
to opioid substitution treatment (OST) in primary care for opioid dependent people, could be 
considered a success.  First, we demonstrated that opioid dependent people who inject drugs 
(PWID) could be recruited and randomised into the trial from a low threshold agency and followed-
up successfully.  Recruitment was generally ahead of schedule and the follow-up rate was 80-98%.  
Second, there was active involvement from users and practitioners’ in the formulation of the 
hypothesis, development of the intervention and conduct of the trial.  Individuals who had 
previously injected drugs agreed to be members of the Trial Steering Group and actively contributed 
at these meetings. They were also involved in the discussion of the results.  
 Third, a nested qualitative study reported that the intervention seemed acceptable both to 
participants and practitioners involved in the trial. Taking part in the trial enabled intervention arm 
participants to obtain treatment for their problematic drug use.  
However, there was insufficient evidence of an intervention effect with similar outcomes for OST 
and reductions in substance use at 3 months between the intervention and control arm. Quality of 
life over the duration of the trial improved, but again there was insufficient evidence for any 
adjusted quality of life gains between the groups.   
 
What is already known on this topic 
People who inject drugs have poorer health and quality of life, are more likely to be engaging in 
crime thus, promoting OST and recovery from drug use is a key goal in the prevention of drug 
related harm.    
 
What this study adds 
The SCID feasibility trial demonstrates that it is possible to conduct an RCT, 3 month follow-up of a 
novel intervention suggested by patients/ users and peer workers to increase the uptake of OST for 
people who inject heroin. We also provide further evidence that health quality of life (HQoL) of 
PWID is poor compared to general population (7, 23).  For example, the average HQoL of  young 
adults (30-44) is near 1 whereas our sample of dependent opioid users/PWID reported average 
scores markedly lower at 0.6 (24). Within current policy, the key focus is upon recovery. Thus, whilst 
this feasibility study focused upon the uptake of OST and not recovery, we suggest that the findings 
contribute to drug treatment services in beginning the process to promoting recovery.  
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To our knowledge this study is the first to investigate an intervention such as SCID, with accelerated 
access to OST in primary care facilitated by peer support volunteers. The importance of peers in 
substance misuse treatment is well recognised (25). Low threshold access to methadone through a 
mobile bus was offered to PWID in Amsterdam at peak of HIV epidemic; and several trials have 
shown how intense case management can increase OST uptake (9, 11, 26). Bristol in contrast to 
other sites in the UK, has developed an extensive shared care network of OST delivered in primary 
care.  The average wait for an appointment and initiation onto OST is 3-5 days following a first GP 
appointment, and a high proportion of PWID are in treatment (as shown by the high numbers and 
proportion of people attending the NSP who were ineligible for the trial because they were already 
in treatment).  We believe this to be relatively rapid compared to other cities in UK and elsewhere, 
and therefore provides an ideal setting to test an intervention that offers immediate access to OST. 
It was important to conduct the feasibility trial in a site like Bristol with good access to OST so that 
any difference in the outcome could be attributed to the intervention rather than restrictions to 
OST.  We show that an intervention like SCID may be unnecessary, but that further work on case 
management in low-threshold agencies to encourage OST uptake could be worthwhile.  
 
There is limited information on health utilities or quality of life (HQoL) of PWID prior and during 
treatment, which can limit evaluations of cost effectiveness of interventions in this group (23, 27, 
28).   Several studies have shown that HQoL generally is depressed compared to general population 
(7). However, whilst some studies show HQoL improves during and after OST this may not be 
sustained in the longer term (29). Thus, the importance of psychological well-being and providing 
practical, social and environmental support should also be considered (30).  We found that OST 
increased HQoL though it was still poor in contrast to the general population (24). We also suggest 
that the SF12 questionnaire may be preferable to obtain quality of life measurements in future 
studies in PWID and opioid dependent people due to less variability and its greater weight given to 
mental health domains.  
 
Limitations 
There is controversy over how feasibility studies should be used to guide future evaluations, 
especially if the decision is based on evidence of a small or clinically unimportant effect (31).  
However, at 100 participants, our study is as large as several other recent trials (32-35).  Though the 
confidence interval of the intervention effect (0.54 to 2.57] was consistent with a decrease of nearly 
50% or greater than 2.5 fold increase, the high number and proportion of the control in OST at 3 
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months suggests that there is little further improvement that could be made by the intervention, 
and that the specific intervention we developed may not be required to encourage PWID into OST.   
 
 
Secondly, did the control receive treatment as usual? Participants who attended our recruitment site 
and were not in treatment were invited to make an appointment with their local general practitioner 
(GP) to initiate OST.  Additionally, our control group were subject to an approximately hour long 
baseline interview where they gave consent for the study and follow-up , provided information on 
their current drug use and quality of life and were also compensated for their time.  Our nested 
qualitative study suggests that this extra hour providing information may have inadvertently 
provided time for reflection that motivated these participants to seek treatment (22).  This does not 
invalidate this feasibility trial, but does suggest that a new trial of enhanced case management which 
involves a more considered assessment of current drug use and quality of life informed by 
psychological theory may be warranted.    
 
Conclusions 
In conclusion, the feasibility aspects of the trial were successful as we demonstrate that PWID could 
be recruited into the trial and followed-up successfully. There was insufficient evidence of an effect 
for the intervention compared to intensive case management. Thus, further development and 
evaluation of case management approaches is warranted. 
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Box 1: quotes from participants about peer volunteers  
 
 
Box 2 quotes from participants illustrating how taking part in the trial increased self-efficacy and 
motivation. 
 
 
 “It made me think a lot actually about myself…I don’t actually sit down and think about my overall 
day, usage or anything like that. But when I was going through the questionnaire I actually did think 
about “God … things aren’t quite as good as I thought they were” (participant #219; Female; 28y). 
 
“ I suppose it made me get off me bum and go and get a script somewhere else” (participant #002; 
Male; 43y). 
 
  
“He [peer support worker] explained to me about how it changed his life when he stops using 
heroin. Yeah I see how this guy’s happy…and I’m thinking about this, I want to change my life” 
(participant #211; male; 37yr). 
 
“With that support I didn’t feel like turning back half way which, if I had been on my own, then I 
probably would have done” (participant #101; female; 36yr). 
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Figure 1. Script in a Day recruitment graph 
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Figure 2 SCID flow diagram of participants recruited into the trial  
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Figure 3. Evolution of quality of life preference scores for patients completing both the EQ-5D and 
the SF-12  
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Table I Patients recruited and baseline characteristics (percentages with numbers or means with 
standard deviations in brackets). 
 
Variable Intervention 
sample 
Control sample Whole sample 
Gender- female 14.3% (7/49) 17.6% (9/51) 16% (16/100) 
White British/Irish/other 95.9% (47/49) 92.0% (46/50) 93.9% (93/99) 
Caribbean, Asian, Other or Mixed 
race 
4.1% (2/49) 8.0% (4/50) 6.1% (6/99) 
Registered with a GP 71.4% (35/49) 66.7% (34/51) 69% (69/100) 
Previous treatment for drug use. 89.8% (44/49) 90.2% (46/51) 90% (90/100) 
Currently receiving support from 
mental health team 
12.2% (6/41) 11.8% (6/51) 12% (12/100) 
No fixed abode 20.4% (10/49) 31.4% (16/51) 26% (26/100) 
TOP baseline data:    
No. of days using alcohol in last 28 10.8 (11.5) 11.2 (12.2) 11 (11.8) 
No. of days using opiates in last 28 23.2 (6.7) 24.1 (6.6) 23.7 (6.6) 
No of days using crack in last 28 16.2 (10.5) 16.7 (10.7) 16.4 (10.6) 
No of days injecting drugs in last 28 22.8 (7.4) 24.7 (6) 23.8 (6.8) 
Health related quality of life:    
EQ-5D score (SD) (N) 0.61 (0.24) (49) 0.54 (0.30) (51) 0.57 (0.28) (100) 
EQ-5D VAS (0 to 100 scale) 51.0 (20.2) 49.0 (20.9) 50.0 (20.5) 
SF-6D score (SD) (N) 0.59 (0.12) (48) 0.59 (0.12) (47) 0.59 (0.12) (95) 
SF 12 physical HRQL score (0 to 100 
scale) 44.1 (25.4) 43.1 (25.6) 43.6 (25.4) 
SF 12 mental HRQL score (0 to 100 
scale) 33.5 (21.5) 31.8 (21.6) 32.6 (21.5) 
 
  
20 
Table II Trial feasibility outcomes with 95% confidence intervals 
 
Pilot Statistic number Rate/Percentage with 
95% confidence 
interval 
Average number of patients screened per 
session* 
1371 screened from 90 
sessions attended 
15.2 [14.4, 16.1] 
Percentage Eligible  311 / 1371 22.7% [20.5, 25.0] 
Percentage Declined  211 / 311 67.8% [62.3, 73.0] 
Average number of consented patients  per 
session* 
100 recruits from 90 
sessions attended 
1.1 [0.90, 1.35] 
Recruitment percentage 100 / 311 32.2% [27.0, 37.7] 
Percentage randomised to the intervention 49 / 100 49% 
Face to face follow-up  85 / 99 85.9% [77.4, 92.0] 
Face to face follow-up: intervention group 41 / 49 83.7% [70.3, 92.7] 
Face to face follow-up: control group 44 / 51 86.3% [73.7, 94.3] 
Medical records follow-up  88 / 99 88.9% [81.0, 94.3] 
Medical records follow-up: intervention group 47 / 48 97.9% [88.9, 99.9] 
Medical records follow-up: control group 41 / 51 80.4% [66.9, 90.2] 
Attended GP appointment (intervention only) 47 / 49 95.9% [86.2, 99.5] 
Received a same day script (intervention only) 43 / 49 87.8% [75.2, 95.4] 
* Calculated using the exact Poisson method 
 Deceased patient omitted from the denominator 
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Table III. Outcomes at 3 months as measured by OST, or days abstinence from opiates  
 
Outcome measure Percentage success at 
3 months 
intervention  
Percentage success 
at 3 months control 
Odds ratio of 
success in 
intervention 
compared with 
control [95% 
confidence interval 
Self-report OST at 3 months 57.1 (24/42) 54.5 (24/44) 1.11 [0.47, 2.60] 
Medical records OST at 3 
months 
47.9 (23/48)  46.3 (19/41) 1.07 [0.46, 2.46] 
OST at 3mth (self-report or 
medical records) 
52.1 (25/48)  51.1 (24/47) 1.04 [0.466, 2.33] 
ITT OST at 3mth – intention 
to treat (those with no 
medical records are 
included as not on OST at 3 
months)  
51.0 (25/49)  47.1 (24/51) 1.17 [0.54, 2.57] 
Self-reported reduction in 
days using opiates  in the 
last month compared with 
baseline 
78.6 (33/42)  72.7 (32/44) 1.38 [0.51, 3.71] 
No opiate use in the last 28 
days 
33.3 (14/42)  22.7 (10/44) 1.70 [0.66, 4.41] 
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Table IV: Change in self-reported substance use and quality of life from baseline to 3 months for 
those who completed the questionnaire at both time points (n=85)  
 
 Mean (SD) 
baseline 
Mean (SD) 3 
months 
Effect size for 
change at 3 
months compared 
with baseline 
Effect size for 
difference between 
intervention and 
control at 3 months 
Substance Use  (number of days used in the last 
28 days) 
  
Alcohol 11.1 (11.5)  9.1 (11.4) 0.20 [-0.02, 0.42] -0.05 [-0.50, 0.39] 
Opiates 23.5 (6.8)  9.9 (11.0) 1.15 [0.93, 1.36] 0.19 [-0.25, 0.63] 
Crack 16.5 (10.6)  7.0 (9.4) 0.82 [0.60, 1.04] 0.07 [-0.37, 0.51] 
Cocaine 0.16 (1.11)  0.14 (0.90) 0.06 [-0.15, 0.28] -0.16 [-0.60, 0.28] 
Amphetamine 0.86 (4.06) 0.46 (3.16) 0.09 [-0.13, 0.31] 0.13 [0.31, 0.57] 
Cannabis 8.4 (10.4) 6.8 (10.2) 0.16 [-0.06, 0.37] 0.06 [-0.38, 0.50] 
Other 4.6 (8.5) 3.0 (7.6) 0.17 [-0.05, 0.39] 0.39 [-0.06, 0.83] 
Injecting 23.4 (38.5) 9.8 (11.4) 1.06 [0.85 1.28] 0.15 [-0.29, 0.59] 
Health Related Quality of life 
EQ-5D VAS  
(0 to 100 scale) 
49.8 (19.9) 60.0 (19.7) 0.45 [0.23, 0.67] -0.06 (-0.50, -0.38) 
SF 12 physical HRQL  
(0 to 100 scale) 
43.0 (23.4) 57.0 (25.3) 0.53 [0.32, 0.75] 0.08 [-0.36, 0.52] 
SF 12 mental HRQL  
(0 to 100 scale) 
33.1 (21.2) 47.7 (25.3) 0.56 [0.35, 0.78] 0.43 [-0.01, 0.87] 
8 domains of the SF-12 (0 to 100 scale) 
Physical health 
domains 
    
Physical functioning 65.9 (31.6) 80.9 (25.5) 0.43 [0.21, 0.65] 0.10 [-0.35, 0.56] 
Role limitation 
physical 
23.4 (38.5) 42.2 (45.2) 0.33 [0.10, 0.56] 0.15 [-0.31, 0.62] 
Bodily Pain 53.6 (29.3) 68.1 (28.2) 0.45 [0.23, 0.66] 0.03 [-0.42, 0.47] 
General Health 29.7 (20.6) 37.9 (25.8) 0.35 [0.13, 0.56] 0.02 [-0.46, 0.42] 
Mental health 
domains 
    
Vitality 35.5 (20.2) 45.5 (26.6) 0.36 [0.14, 0.58] 0.51 [0.06, 0.95] 
Role limitation 
emotional 
20.6 (37.1) 44.4 (46.4) 0.48 [0.26, 0.71] 0.27 [-0.19, 0.72] 
Mental health 38.7 (24.0) 50.7 (22.3) 0.46 [0.24, 0.68] 0.31 [-0.14, 0.75] 
Social functioning 36.9 (28.9) 50.9 (30.2) 0.41 [0.20, 0.63] 0.21 [-0.23, 0.65] 
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Table V – Preference based scores and incremental QALY gains for patients completing both EQ-
5D-5L and SF-12 measures (N=76) 
 
 
 Mean baseline score Mean 3m score   
EQ-5D-5L     
Intervention (n=36) (SD) 0.637 (0.214) 0.688 (0.289) 
Control (n=40) (SD) 0.565 (0.294) 0.705 (0.234) 
QALY gain* [95% CI]  -0.006 [-0.020, 0.008] 
SF-6D   
Intervention (n=36) 0.602 (0.112) 0.675 (0.183) 
Control (n=40) 0.591 (0.121) 0.648 (0.093) 
QALY gain* [95% CI]  0.003 [-0.005, 0.010] 
 
* Adjusted for baseline score, robust standard errors 
 
 
 
Not meeting inclusion 
criteria (n=1060) 
 
